Skip to main content

Table 4 Adverse events after baseline but before recurrence of parasitaemia occurring in > 5% of patients, by body weight group

From: Evaluation of the efficacy and safety of artemether-lumefantrine in the treatment of acute uncomplicated Plasmodium falciparum malaria in Nigerian infants and children

Adverse Events n (%)
  BWG1
5-<10 kg
(N = 50)
BWG2
10-<15 kg
(N = 37)
BWG3
15-<25 kg
(N = 16)
Ttotal
5-<25 kg
(N = 103)
Anaemia 32 (64.0) 20 (54.1) 7 (43.8) 59 (57.3)
Cough 20 (40.0) 11 (29.7) 2 (12.5) 33 (32.0)
Hepatomegaly 9 (18.0) 12 (32.4) 5 (31.3) 26 (25.2)
Respiratory tract infection 21 (42.0) 9 (24.3) 1 (6.3) 31 (30.1)
Splenomegaly 10 (20.0) 9 (24.3) 2 (12.5) 21 (20.4)
Diarrhoea 11 (22.0) 7 (18.9) 2 (12.5) 20 (19.4)
Vomiting 10 (20.0) 3 (8.1) 5 (31.3) 18 (17.5)
Rashes 11 (22.0) 5 (13.5) 1 (6.3) 17 (16.5)
Anorexia 9 (18.0) 5 (13.5) 1 (6.3) 15 (14.6)
Clonus 7 (14.0) 5 (13.5) 1 (6.3) 13 (12.6)
Insomnia 7 (14.0) 3 (8.1) 1 (6.3) 11 (10.7)
Catarrh 4 (8.0) 5 (13.5) 0 (0.0) 9 (8.7)
Hypothermia 5 (10.0) 1 (2.7) 0 (0.0) 6 (5.8)
Hyperreflexia 3 (6.0) 2 (5.4) 1 (6.3) 6 (5.8)